Instrument Inactif

Communiqués Kuros Biosciences AG Swiss Exchange

Actions

CH0011025217

Cours en clôture Swiss Exchange Autres places de cotation
- ^CHF	-

24/04	Bourse Zurich: retour dans le rouge, Roche plombe l'indice	AW
24/04	Les ventes de Kuros s'envolent	AW

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority over Autograft	26/06	AQ
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft	25/06	EQ
Kuros Biosciences : Minutes of AGM, 17 April 2024	16/05	PU
Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales	24/04	EQ
Annual General Meeting of Kuros Biosciences approves all resolutions	17/04	EQ
Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023	13/03	EQ
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update	08/03	EQ
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference	01/02	EQ
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand	31/01	EQ
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA	04/01	EQ
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA	27/12	EQ
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages	28/11	EQ
Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management	12/10/23	EQ
Kuros Biosciences : Reports Results for First Half 2023	31/08/23	PU
Kuros Biosciences : Investor Webcast Presentation, H1 2023	23/08/23	PU
Kuros Biosciences "doing extremely well" in innovative spinal fusion treatments	11/08/23	AQ
Kuros Biosciences : Investor Presentation, 2023	09/08/23	PU
Kuros Biosciences Reports Results for First Half 2023	09/08/23	EQ
Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial	13/07/23	EQ
Kuros Biosciences : Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial	13/07/23	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Kuros Biosciences AG Swiss Exchange

Actions

CH0011025217

Communiqués

Filtres